Literature DB >> 15682332

Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.

Diederick Stoffers1, Jan Booij, Lisette Bosscher, Ania Winogrodzka, Erik C Wolters, Henk W Berendse.   

Abstract

PURPOSE: Previous studies using dopamine transporter single-photon emission computed tomography (SPECT) to try and distinguish between patients with idiopathic Parkinson's disease (IPD) and patients with atypical parkinsonian syndromes (APS) have mainly focussed on patients with an already established clinical diagnosis of several years' duration. Differences in the pattern of striatal involvement between IPD and APS have been found in only few studies. We hypothesized that distinguishing SPECT features might be most pronounced at an early disease stage, and the purpose of the present study was to investigate this hypothesis.
METHODS: The study included 72 patients with an initial clinical diagnosis of IPD, supported by decreased striatal [(123)I]beta-CIT binding on baseline SPECT. In ten patients, the diagnosis was changed to APS over a mean follow-up period of 62 months. We retrospectively compared the patterns of striatal involvement on the baseline SPECT scans between the group of patients (re)diagnosed with APS and the remaining 62 patients in whom a diagnosis of IPD was maintained.
RESULTS: In the group of patients with APS, baseline [(123)I]beta-CIT binding in both caudate nuclei was lower than in the group of patients with IPD. In addition, putamen to caudate binding ratios were higher in the group of APS patients. In spite of these differences, individual binding values showed considerable overlap between the groups.
CONCLUSION: [(123)I]beta-CIT SPECT scanning in early-stage, untreated parkinsonian patients revealed a relative sparing of the caudate nucleus in patients with IPD as compared to patients later (re)diagnosed with APS. Nevertheless, the pattern of striatal involvement appears to have little predictive value for a later re-diagnosis of APS in individual cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682332     DOI: 10.1007/s00259-004-1733-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

Authors:  S J Kish; K Shannak; O Hornykiewicz
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

2.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

3.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy.

Authors:  M Ruberg; F Javoy-Agid; E Hirsch; B Scatton; R LHeureux; J J Hauw; C Duyckaerts; F Gray; A Morel-Maroger; A Rascol
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Authors:  R B Innis; K L Marek; K Sheff; S Zoghbi; J Castronuovo; A Feigin; J P Seibyl
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

Review 6.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

7.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.

Authors:  T Brücke; S Asenbaum; W Pirker; S Djamshidian; S Wenger; C Wöber; C Müller; I Podreka
Journal:  J Neural Transm Suppl       Date:  1997

8.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

9.  Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography.

Authors:  C Messa; M A Volonté; F Fazio; F Zito; A Carpinelli; A d'Amico; G Rizzo; R M Moresco; E Paulesu; M Franceschi; G Lucignani
Journal:  Eur J Nucl Med       Date:  1998-09

10.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.

Authors:  R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

View more
  5 in total

1.  Predictive value of dopamine transporter SPECT imaging with [¹²³I]PE2I in patients with subtle parkinsonian symptoms.

Authors:  Morten Ziebell; Birgitte B Andersen; Gerda Thomsen; Lars H Pinborg; Merete Karlsborg; Steen G Hasselbalch; Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-18       Impact factor: 9.236

2.  FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.

Authors:  Sanne K Meles; David Vadasz; Remco J Renken; Elisabeth Sittig-Wiegand; Geert Mayer; Candan Depboylu; Kathrin Reetz; Sebastiaan Overeem; Angelique Pijpers; Fransje E Reesink; Teus van Laar; Lisette Heinen; Laura K Teune; Helmut Höffken; Marcus Luster; Karl Kesper; Sofie M Adriaanse; Jan Booij; Klaus L Leenders; Wolfgang H Oertel
Journal:  Mov Disord       Date:  2017-07-22       Impact factor: 10.338

3.  SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias.

Authors:  Sven R Suwijn; Henk W Berendse; Constant Vm Verschuur; Ania Winogrodzka; Rob Ma de Bie; Jan Booij
Journal:  EJNMMI Res       Date:  2013-06-05       Impact factor: 3.138

4.  Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.

Authors:  Annemarie M M Vlaar; Marinus J P G van Kroonenburgh; Alfons G H Kessels; Wim E J Weber
Journal:  BMC Neurol       Date:  2007-09-01       Impact factor: 2.474

5.  Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy.

Authors:  S R Suwijn; H W Berendse; C V M Verschuur; R M A de Bie; J Booij
Journal:  ISRN Neurol       Date:  2014-02-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.